Trial Eligibility
Have you or someone you know been diagnosed with heart failure with severely reduced ejection fraction?
COMET-HF
COMET-HF is recruiting participants for a clinical trial of omecamtiv mecarbil, a study medicine for heart failure with reduced (low) ejection fraction (HFrEF).
Participating in a clinical trial is an important decision. We encourage potential participants to talk with their usual doctors, their caregivers, and their study doctor about participating in this study.
Who may be a good fit for this study?
Adults with severe HFrEF may be a good fit for this study if they:
- Are 18 to 85 years old
- Have been diagnosed with heart failure with severely reduced (low) ejection fraction
- Have been hospitalized in the past 6 months for new or worsening heart failure symptoms
- Are being treated with guideline-directed medical therapy for heart failure
Additional enrollment requirements are listed in the study record on ClinicalTrials.gov (NCT06736574).
Learn more about the COMET-HF study on the Frequently Asked Questions page.
Omecamtiv mecarbil is an investigational drug, which means it has not been approved by any regulatory agency. Its safety and effectiveness have not been established.
Interested in participating in COMET-HF?
This study will enroll participants in the United States, Canada, and Europe.
Details about enrollment requirements and contact information for study sites are provided in the study record on ClinicalTrials.gov (NCT06736574). Sites are added to the study record as they begin enrolling participants.
People who want to learn more about the COMET-HF study may email [email protected].